MARKET

RLYB

RLYB

Rallybio Corp
NASDAQ
0.6568
-0.0192
-2.84%
After Hours: 0.6579 +0.0011 +0.17% 19:20 01/16 EST
OPEN
0.6780
PREV CLOSE
0.6760
HIGH
0.6820
LOW
0.6384
VOLUME
198.49K
TURNOVER
--
52 WEEK HIGH
0.9600
52 WEEK LOW
0.2201
MARKET CAP
27.75M
P/E (TTM)
-2.0589
1D
5D
1M
3M
1Y
5Y
1D
Rallybio Terminates Phase 2 FNAIT Pregnancy Study: What Investors Need to Know
TipRanks · 4d ago
Weekly Report: what happened at RLYB last week (0105-0109)?
Weekly Report · 5d ago
Rallybio’s Phase 2 FNAIT Prevention Study Reaches Completion: What Investors Should Watch Next
TipRanks · 01/09 16:30
Weekly Report: what happened at RLYB last week (1229-0102)?
Weekly Report · 01/05 10:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 12/31/2025 21:05
Weekly Report: what happened at RLYB last week (1222-1226)?
Weekly Report · 12/29/2025 10:08
Rallybio Corporation Announces Date for Upcoming Special Stockholders Meeting
Reuters · 12/23/2025 21:02
Weekly Report: what happened at RLYB last week (1215-1219)?
Weekly Report · 12/22/2025 10:08
More
About RLYB
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Webull offers Rallybio Corp stock information, including NASDAQ: RLYB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLYB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLYB stock methods without spending real money on the virtual paper trading platform.